RU2607080C2 - Спиро-конденсированные производные циклогексана в качестве ингибиторов hsl, полезные для лечения диабета - Google Patents
Спиро-конденсированные производные циклогексана в качестве ингибиторов hsl, полезные для лечения диабета Download PDFInfo
- Publication number
- RU2607080C2 RU2607080C2 RU2012119706A RU2012119706A RU2607080C2 RU 2607080 C2 RU2607080 C2 RU 2607080C2 RU 2012119706 A RU2012119706 A RU 2012119706A RU 2012119706 A RU2012119706 A RU 2012119706A RU 2607080 C2 RU2607080 C2 RU 2607080C2
- Authority
- RU
- Russia
- Prior art keywords
- azaspiro
- decan
- hydroxy
- phenyl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09173178.6 | 2009-10-15 | ||
| EP09173178 | 2009-10-15 | ||
| PCT/EP2010/065232 WO2011045292A1 (en) | 2009-10-15 | 2010-10-12 | Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012119706A RU2012119706A (ru) | 2013-11-20 |
| RU2607080C2 true RU2607080C2 (ru) | 2017-01-10 |
Family
ID=43093680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012119706A RU2607080C2 (ru) | 2009-10-15 | 2010-10-12 | Спиро-конденсированные производные циклогексана в качестве ингибиторов hsl, полезные для лечения диабета |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8440710B2 (enExample) |
| EP (1) | EP2488493B1 (enExample) |
| JP (1) | JP5749272B2 (enExample) |
| KR (1) | KR101576328B1 (enExample) |
| CN (1) | CN102858743B (enExample) |
| AR (1) | AR078619A1 (enExample) |
| AU (1) | AU2010305859A1 (enExample) |
| BR (1) | BR112012008962A2 (enExample) |
| CA (1) | CA2776457A1 (enExample) |
| CL (1) | CL2012000937A1 (enExample) |
| ES (1) | ES2538005T3 (enExample) |
| IL (1) | IL218958A0 (enExample) |
| IN (1) | IN2012DN03337A (enExample) |
| MX (1) | MX2012004311A (enExample) |
| PE (1) | PE20121732A1 (enExample) |
| PH (1) | PH12012500630A1 (enExample) |
| RU (1) | RU2607080C2 (enExample) |
| TW (1) | TW201118068A (enExample) |
| WO (1) | WO2011045292A1 (enExample) |
| ZA (1) | ZA201202613B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120834A1 (es) | 2009-03-23 | 2012-07-25 | Glenmark Pharmaceuticals Sa | Derivados de furopirimidindiona como moduladores de trpa1 |
| US8097634B2 (en) * | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| US8722721B2 (en) * | 2011-03-16 | 2014-05-13 | Hoffmann-La Roche Inc. | SEC-hydroxycyclohexyl derivatives |
| US8703807B2 (en) * | 2011-03-17 | 2014-04-22 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
| US8809384B2 (en) * | 2011-03-25 | 2014-08-19 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
| CN103319395B (zh) * | 2013-04-08 | 2014-09-24 | 武汉罗化科技有限公司 | 一种4-氟靛红的工业化制备方法及其产品 |
| WO2015103756A1 (en) | 2014-01-09 | 2015-07-16 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| UY36060A (es) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | Compuestos de azol sustituidos con amida |
| JP7212693B2 (ja) | 2017-11-01 | 2023-01-25 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレーターとしての架橋二環化合物 |
| US11286252B2 (en) | 2017-11-01 | 2022-03-29 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid X receptor modulators |
| US11168079B2 (en) | 2017-11-01 | 2021-11-09 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
| KR102731925B1 (ko) | 2017-11-01 | 2024-11-18 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물 |
| CN111278821B (zh) | 2017-11-01 | 2023-10-03 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的螺环化合物 |
| CN109369354B (zh) * | 2018-12-15 | 2021-07-09 | 浦拉司科技（上海）有限责任公司 | 一种4,4,4-三氟丁醇的合成方法 |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| JP7449300B2 (ja) | 2019-02-15 | 2024-03-13 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物 |
| JP7465883B2 (ja) | 2019-02-15 | 2024-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレータとしての置換二環式化合物 |
| US12319676B2 (en) | 2019-02-15 | 2025-06-03 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid X receptor modulators |
| CN117567380B (zh) * | 2023-11-17 | 2025-10-17 | 广东药科大学附属第一医院 | 三唑类hsl抑制剂、制备方法及其用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004035550A1 (de) * | 2002-10-12 | 2004-04-29 | Aventis Pharma Deutschland Gmbh | Neue bicyclische inhibitoren der hormon sensitiven lipase |
| WO2007103719A2 (en) * | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| WO2007127763A2 (en) * | 2006-04-25 | 2007-11-08 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| EA009292B1 (ru) * | 2004-05-19 | 2007-12-28 | Ле Лаборатуар Сервье | Новые соединения пирролидина и тиазолидина, способ их получения и фармацевтические композиции, которые их содержат |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| CA2549510A1 (en) | 2003-12-16 | 2005-07-07 | Pfizer Products Inc. | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors |
| EP2021337B1 (en) * | 2006-04-25 | 2010-01-13 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| GB0705656D0 (en) | 2007-03-23 | 2007-05-02 | Addex Pharmaceuticals Sa | Novel compounds E1 |
-
2010
- 2010-10-08 US US12/900,621 patent/US8440710B2/en not_active Expired - Fee Related
- 2010-10-12 CA CA2776457A patent/CA2776457A1/en not_active Abandoned
- 2010-10-12 CN CN201080046313.0A patent/CN102858743B/zh not_active Expired - Fee Related
- 2010-10-12 JP JP2012533604A patent/JP5749272B2/ja not_active Expired - Fee Related
- 2010-10-12 KR KR1020127012343A patent/KR101576328B1/ko not_active Expired - Fee Related
- 2010-10-12 PH PH1/2012/500630A patent/PH12012500630A1/en unknown
- 2010-10-12 RU RU2012119706A patent/RU2607080C2/ru not_active IP Right Cessation
- 2010-10-12 PE PE2012000489A patent/PE20121732A1/es not_active Application Discontinuation
- 2010-10-12 WO PCT/EP2010/065232 patent/WO2011045292A1/en not_active Ceased
- 2010-10-12 MX MX2012004311A patent/MX2012004311A/es active IP Right Grant
- 2010-10-12 BR BR112012008962A patent/BR112012008962A2/pt not_active IP Right Cessation
- 2010-10-12 EP EP10770764.8A patent/EP2488493B1/en not_active Not-in-force
- 2010-10-12 IN IN3337DEN2012 patent/IN2012DN03337A/en unknown
- 2010-10-12 ES ES10770764.8T patent/ES2538005T3/es active Active
- 2010-10-12 TW TW099134747A patent/TW201118068A/zh unknown
- 2010-10-12 AU AU2010305859A patent/AU2010305859A1/en not_active Abandoned
- 2010-10-13 AR ARP100103732A patent/AR078619A1/es unknown
-
2012
- 2012-03-29 IL IL218958A patent/IL218958A0/en unknown
- 2012-04-11 ZA ZA2012/02613A patent/ZA201202613B/en unknown
- 2012-04-13 CL CL2012000937A patent/CL2012000937A1/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004035550A1 (de) * | 2002-10-12 | 2004-04-29 | Aventis Pharma Deutschland Gmbh | Neue bicyclische inhibitoren der hormon sensitiven lipase |
| EA009292B1 (ru) * | 2004-05-19 | 2007-12-28 | Ле Лаборатуар Сервье | Новые соединения пирролидина и тиазолидина, способ их получения и фармацевтические композиции, которые их содержат |
| WO2007103719A2 (en) * | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| WO2007127763A2 (en) * | 2006-04-25 | 2007-11-08 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
Non-Patent Citations (4)
| Title |
|---|
| HELVETICA CHIMICA ACTA, 1977, v. 60, n.5, p. 1650-1656. * |
| HELVETICA CHIMICA ACTA, 1977, v. 60, n.5, p. 1650-1656. Tetrahedron Letters, 1998, 39, p. 8413-8416. Tetrahedron Letters, 1988, v.29, n. 49, p. 6421-6424. * |
| Tetrahedron Letters, 1988, v.29, n. 49, p. 6421-6424. * |
| Tetrahedron Letters, 1998, 39, p. 8413-8416. * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011045292A1 (en) | 2011-04-21 |
| IL218958A0 (en) | 2012-06-28 |
| KR20120074304A (ko) | 2012-07-05 |
| PH12012500630A1 (en) | 2012-10-22 |
| CN102858743A (zh) | 2013-01-02 |
| KR101576328B1 (ko) | 2015-12-10 |
| PE20121732A1 (es) | 2012-12-28 |
| IN2012DN03337A (enExample) | 2015-10-23 |
| JP2013507421A (ja) | 2013-03-04 |
| US20110092512A1 (en) | 2011-04-21 |
| RU2012119706A (ru) | 2013-11-20 |
| JP5749272B2 (ja) | 2015-07-15 |
| CL2012000937A1 (es) | 2012-09-14 |
| HK1179957A1 (en) | 2013-10-11 |
| MX2012004311A (es) | 2012-04-30 |
| CA2776457A1 (en) | 2011-04-21 |
| US8440710B2 (en) | 2013-05-14 |
| CN102858743B (zh) | 2015-06-10 |
| ES2538005T3 (es) | 2015-06-16 |
| EP2488493A1 (en) | 2012-08-22 |
| BR112012008962A2 (pt) | 2019-09-24 |
| ZA201202613B (en) | 2013-01-30 |
| AU2010305859A1 (en) | 2012-06-07 |
| EP2488493B1 (en) | 2015-04-15 |
| TW201118068A (en) | 2011-06-01 |
| AR078619A1 (es) | 2011-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5749272B2 (ja) | 糖尿病処置のために有用なｈｓｌ阻害剤としてのスピロ−縮合シクロヘキサン誘導体 | |
| KR101438263B1 (ko) | Ｈｓｌ 억제제로서의 아자환형 스파이로유도체 | |
| WO1996014846A1 (en) | Dihydropyrimidines and uses thereof | |
| ES2377556T9 (es) | Compuestos que contienen nitrógeno, que tienen actividad inhibitoria quinasa, y composiciones farmacéuticas que los comprenden | |
| WO2014146493A1 (en) | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | |
| WO2011029808A1 (en) | Hsl inhibitors useful in the treatment of diabetes | |
| US6727257B1 (en) | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines | |
| CN103415506B (zh) | 作为用于治疗糖尿病的hsl抑制剂的仲-羟基环己基衍生物 | |
| TWI517851B (zh) | 含２，５，７－經取代唑并嘧啶環之雜環羧酸衍生物 | |
| WO2009150388A1 (fr) | NOUVEAUX DERIVES DE (PIPERAZINYL PONTE)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75 | |
| JP2002532480A (ja) | モルホリノン及びモルホリン誘導体、ならびにその使用 | |
| KR20140011335A (ko) | 아자스피로데카논 화합물 | |
| KR20140025411A (ko) | Hsl 억제제로서의 신규 아자스피로데칸온 화합물 | |
| JP4748162B2 (ja) | Ｎ−ジヒドロキシアルキル置換２−オキソイミダゾール誘導体 | |
| RU2603263C2 (ru) | Новые азациклические соединения | |
| US8497288B2 (en) | Hexahydropyrroloimidazolone compounds | |
| TW202523331A (zh) | 作為sstr4激動劑之(2s,5r)-5-(羥甲基)嗎啉-2-甲醯胺 | |
| JP2002532525A (ja) | ジヒドロピリミジンおよびその使用 | |
| KR20140090645A (ko) | 당뇨병 치료에 유용한 ｈｓｌ 억제제로서의 스파이로-축합된 사이클로헥산 유도체 | |
| HK1179957B (en) | Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes | |
| HK1190706B (en) | Sec-hydroxycyclohexyl derivatives as hsl inhibitors for the treatment diabetes | |
| JP2008535816A (ja) | ピペリジニル置換されたシクロヘキサン−１，４−ジアミン類 | |
| TW201242947A (en) | New azaspirodecanone compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20171013 |